INVESTIGACIÓN

Publicaciones

[1] Rodriguez-Ibeas, R. (2000): “A Hybrid Equilibrium in Segmented Markets: The 3-Firm Case”. Journal of Economics, Vol. 72(1), pp 81-97

[2] Rodríguez-Ibeas, R. (2002): “Regulatory Enforcement with Discretionary Fining and Litigation’’ Bulletin of Economic Research, Vol. 54 (2), pp. 105-118

[3] Rodríguez-Ibeas, R. (2003): “Honesty in Environmental Regulation” Journal of Regulatory Economics 24 (1), 35-48

[4] Antoñanzas, F, R. Rodríguez, J. A. Sacristán y R. Illa (2005): “Los medicamentos en la Unión Europea: el tándem comercio-salud” Gaceta Sanitaria 19(2), 151-167

[5] Rodríguez-Ibeas, R. (2006): “Environmental Regulatory Enforcement with “Green” Consumers” Spanish Economic Review Vol. 8 (4), 271-283

[6] Antoñanzas, F., Juárez, C., Rodríguez, R., Ramírez, M., Lorente, R., Ginestal, J. (2006): “Utilización de un impuesto sobre ventas de tabaco en la fase minorista destinado a la financiación de la farmacoterapia para la deshabituación tabáquica” Gaceta Sanitaria vol. 20 (Supl. 3), 33-41

[7] Rodríguez-Ibeas, R. (2007): “Environmental Product Differentiation and Environmental Awareness” Environmental and Resource Economics, Vol. 36 (2), 237-54

[8] Antoñanzas, F, R. Rodríguez (2007): “Tobacco policies in the European Union: a need for state and continental harmonisation?” The European Journal of Health Economics 8 (4), 301-304

[9] Antoñanzas, F, Rodríguez-Ibeas, R., Barco, E., Ramirez, M., M. Pinillos (2008): “Alcohol consumption in the EU: health economics and policy issues under a permanent debate”. European Journal of Health Economics 9, 1-6

[10] Carmelo Juarez-Castello y Roberto Rodríguez-Ibeas (2008): “Comentario: Coste-efectividad e impacto presupuestario en la toma de decisiones de introducción de nuevas tecnologías”. Gaceta Sanitaria 22(6): 593-595.

[11] Antoñanzas, F, Juárez, C., Pinillos, M., Lorente, R, Hutter, F. y R. Rodríguez-Ibeas (2009): “Transferability indices for health economic evaluations: Methods and Applications”. Health Economics 18 (6), 629-643

[12] Antoñanzas, F. and Rodriguez, R (2010): “Feeding the economics of obesity in the EU in a healthy way”. The European Journal of Health Economics: Volume 11 (4): 351-53

[13] Antoñanzas, F, Juárez-Castelló, C y R. Rodríguez-Ibeas (2011): “Innovation, loyalty and generic competition in pharmaceutical markets”. SERIEs Journal 2 (1): 75-95

[14] Antoñanzas, F, Juárez-Castelló, C. y R. Rodríguez-Ibeas (2011): “Should health authorities offer risk-sharing contracts to pharmaceutical firms?” A theoretical approach. Health Economics, Policy and Law 6 (3): 391-403

[15] Fernando Antoñanzas y Roberto Rodríguez-Ibeas (2011) “Healthy vs. Unhealthy Food: A Strategic Choice for Firms and Consumers”, Health Economics Review 2011, 1:4

[16] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2011) “Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad” The European Journal of Health Economics 12 (5), 393-95

[17] Antoñanzas, F., Rodríguez-Ibeas, R., Juárez-Castelló, C., Lorente, R., Hutter, F. y Pinillos, M. (2012). “Genetic Testing in the European Union: Does Economic Evaluation Matter?” The European Journal of Health Economics 13 (5), 651-661

[18] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2012). “Coping with uncertainty on health decisions: assessing new solutions”. The European Journal of Health Economics 13 (4): 375-78

[19] Antoñanzas, F. y Rodríguez-Ibeas, R. (2013) “Channelling health economics research initiatives to improve decision-making processes in the EU”. The European Journal of Health Economics 14 (6): 847-852. Impact Factor: 1.913. Economics: 52/333 (Q1). Health Policy and Services: 25/70 (Q2)

[20] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2013) “Risk-sharing agreements in pharmaceutical markets”. Estudios de Economía Aplicada Vol. 31-2: 359-378

[21] Antoñanzas, F., Villar, Rodríguez-Ibeas, R., Juárez-Castelló, CA. y Mª Reyes Lorente, MR (2014). “Impacto del Real Decreto-Ley 16/2012 sobre copago farmacéutico en el número de recetas y en el gasto farmacéutico”. Revista Española de Salud Pública Vol. 88 (2): 227-243

[22] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2014). “Should the patent system for pharmaceuticals be replaced? A theoretical approach”. Expert Review of Pharmacoeconomics & Outcomes Research Vol. 14(5): 617-626

[23] Hutter, MF, Rodríguez-Ibeas, R. y Antoñanzas, F. (2014) “Methodological reviews of economic evaluations in health care: what do they target?” European Journal of Health Economics 15(8): 829-840

[24] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2014) “El control del gasto farmacéutico en la actual crisis económica”. El Médico 1159: 10-12

[25] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2015). “Is personalized medicine the panacea for health management? Some thoughts on its desirability”. European Journal of Health Economics 16 (5): 455-57. DOI: 10.1007/s10198-014-0665-6

[26] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2015). “Some economics on personalized and predictive medicine”. European Journal of Health Economics 16(9): 985-994. DOI 10.1007/s10198-014-0647-8

[27] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2015). "Efficient health research and improving European’s health. European Journal of Health Economics". European Journal of Health Economics 16(9): 913-915. DOI: 10.1007/s10198-015-0695-8

[28] Antoñanzas, F., Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2016). "Improving health care systems by building ‘more Europe’". European Journal of Health Economics, 17(7), 787-789. DOI: 10.1007/s10198-016-0791-4

[29] Antoñanzas, F.; Juárez-Castelló, C. y Rodríguez-Ibeas, R. (2016) "Implementing personalized medicine with asymmetric information on prevalence rates". Health Economics Review (2016) 6:35. DOI: 10.1186/s13561-016-0113-7